Roche : Invitation to Roche’s Full Year Results 2021 Presentation
January 04, 2022 at 08:09 am EST
Share
Investor Update
Invitation to Roche's Full Year Results 2021 Presentation
Roche will publish its Full Year Results for 2021 prior to the opening of the Swiss Stock Exchange on Thursday, 3 February 2022.
07:00 CET / 06:00 GMT / 01:00 AM EST / 10:00 PM PST (evening before)
Release will be e-mailed and posted on the Roche IR website >clickhere
Presentation slides will be posted on the Roche IR website >click here
14:00 - 16:00 CET / 13:00 - 15:00 GMT
08:00 - 10:00 AM EST / 05:00 - 07:00 AM PST
The webinar will start with presentations by senior management, followed by a Q&A session.
Presenters:
Severin Schwan, CEO Roche Group
Bill Anderson, CEO Roche Pharmaceuticals
Thomas Schinecker, CEO Roche Diagnostics
Alan Hippe, Chief Financial and IT Officer
We would like to invite all interested parties to participate in the webinar and to pre-register for the event here.*
Should you be unable to register for the webinar due to your company IT policy, please send an email to investor.relations@roche.com.
A replay of the webcast will be available via >ir.roche.com
*privacy notice
Best regards,
Karl Mahler Bruno Eschli
Head of Investor Relations Head of Investor Relations
Roche Investor Relations
Dr. Karl Mahler
Phone: +41 61 68-78503
e-mail: karl.mahler@roche.com
Dr. Sabine Borngräber
Phone: +41 61 68-88027
e-mail: sabine.borngraeber@roche.com
Dr. Bruno Eschli
Phone: +41 61 68-75284
e-mail: bruno.eschli@roche.com
Dr. Birgit Masjost
Phone: +41 61 68-84814
e-mail: birgit.masjost@roche.com
Dr. Gerard Tobin
Phone: +41 61 68-72942
e-mail: gerard.tobin@roche.com
Roche Holding AG published this content on 04 January 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 04 January 2022 13:08:01 UTC.
Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.
ROCHE HOLDING AG 
